Anthrax vaccines - PaxVaxAlternative Names: Ad4-PA; Ad4-PA-1; Ad4-PA-Glycosylphosphatidylinositol; Ad4-PA-GPI; Adenovirus serotype 4 vector vaccine against anthrax protective antigen
Latest Information Update: 09 Mar 2016
At a glance
- Originator PaxVax
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Anthrax
Most Recent Events
- 09 Mar 2016 Phase-I development is ongoing in USA
- 01 Oct 2013 Phase-I clinical trials for Anthrax (in volunteers, prevention) in USA (PO)